Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca and Thermo Fisher Scientific.

Medical Crossfire®: Current and Emerging Applications of Liquid Biopsies Across Cancer Care

Release Date: July 14, 2021
Expiration Date: July 14, 2022

Activity Overview

This online, on-demand virtual program brings together faculty experts to discuss recent advances in molecularly targeted agents and immunotherapies for patients with metastatic cancer. These therapies are particularly important for patients with tumors that have specific molecular alterations, necessitating an individualized approach to therapy. Identifying efficacious therapies and avoiding therapies unlikely to be clinically beneficial requires sensitive and specific genetic testing. Tissue biopsy has long been the gold standard for molecular analysis; however, new and emerging liquid biopsy methods offer new possibilities to optimize the diagnosis and treatment of patients with cancer. Topics will include actionable mutations in non–small cell lung cancer (NSCLC), breast cancer, and gastrointestinal (GI) cancers, as well as methods to identify these mutations, when such tests should be ordered, and how to interpret the results of these tests to inform treatment decisions. The optimal application of emerging testing modalities, including liquid biopsies, requires an in-depth understanding of the technology, paired with a coordinated effort by the multidisciplinary health care team.

This educational activity is an archive of the live virtual presentation held on June 7, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Thermo Fisher Scientific.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the attributes and features of liquid and conventional tissue biopsies in the diagnosis and monitoring of cancer
  • Summarize key data concerning the capabilities of new and emerging liquid biopsy technologies for longitudinal disease surveillance to detect evolving tumor heterogeneity
  • Analyze the clinical applicability of circulating tumor cells, circulating tumor DNA, and other biomarkers for treatment stratification and identification of minimal residual disease in select malignancies, including NSCLC, breast cancer, and GI cancers
  • Integrate evolving evidence concerning the use of liquid biopsies to facilitate best practices for their real-world application

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Benjamin P. Levy, MD
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director, Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC

Disclosures: Consultant: AstraZeneca, Janssen Pharmaceuticals, Daiichi Sankyo, Pfizer, Merck & Co, Eli Lilly and Company, Takeda Pharmaceutical Company, Genentech, F. Hoffmann-La Roche.

Charu Aggarwal, MD, MPH
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Consultant: AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo, Blueprint Medicines Corporation, Merck & Co, F. Hoffmann-La Roche.

Aparna R. Parikh, MD
Aparna R. Parikh, MD
Gastrointestinal Oncologist
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support: to MGH Guardant, Natera, Array, Eli Lilly, BMS, Tesaro, Novartis, Macrogenics, PMV Pharm, Takeda, Plexxicon; Consultant: Eli Lilly, Pfizer, Checkmate, Natera DSMC for Roche.

Neelima Vidula, MD
Neelima Vidula, MD
Breast Medical Oncologist
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Disclosures: Neelima Vidula, MD have no relevant financial relationships with ineligible companies to disclose.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By